How Does Concert Pharmaceuticals Inc (CNCE) Stock Rank on Wall Street?

Thursday, September 24, 2020 2:29 PM | InvestorsObserver Analysts

InvestorsObserver is giving Concert Pharmaceuticals Inc (CNCE) an Analyst Rating Rank of 80, meaning CNCE is ranked higher by analysts than 80% of stocks. The average projection by analysts for CNCE is $23.75 over the next 12 months and analyst’s classify the stock as a Strong Buy

Overall Score - 5
Wall Street analysts are rating CNCE a Strong Buy today. Find out what this means to you and get the rest of the rankings on CNCE!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.

Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Concert Pharmaceuticals Inc Stock Today?

Concert Pharmaceuticals Inc (CNCE) stock has fallen -4.69% while the S&P 500 has risen 0.67% as of 2:25 PM on Thursday, Sep 24. CNCE has fallen -$0.46 from the previous closing price of $9.81 on volume of 146,996 shares. Over the past year the S&P 500 has gained 9.17% while CNCE has fallen -11.29%. CNCE lost -$2.70 per share the over the last 12 months.

Click Here to get the full report on Concert Pharmaceuticals Inc (CNCE) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Related Companies